Renal Adjuvant MultiPle Arm Randomised Trial

RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients with initially localised RCC develop metastatic disease following nephrectomy. Need for adjuvant therapy is most marked in the high risk population where outcomes are predictably poor. However, the risk of recurrence in patients who are of intermediate risk of recurrence is not insignificant. Unfortunately, despite showing efficacy in advanced RCC, the results in the adjuvant setting, so far, are inconclus

Trial Details

NCT ID
NCT03288532
Phase
PHASE3
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Durvalumab
  • Tremelimumab
Locations (sample)
  • Aberdeen, United Kingdom|57.14369,-2.09814
  • Bangor, United Kingdom|54.66079,-5.66802
  • Bournemouth, United Kingdom|50.72048,-1.8795
  • Bristol, United Kingdom|51.45523,-2.59665
  • Cambridge, United Kingdom|52.2,0.11667

Key Eligibility Criteria

  • Histologically proven RCC (all cell types of RCC are eligible, except for pure oncocytoma, collecting duct, medullary and transitional cell cancer …
  • At the start of recruitment patients with Leibovich score 3-11 will be eligible for randomisation. MRC CTU at UCL will monitor accrual and stop rec…
  • Patients should have had surgery at least 28 days but no more than 91 days prior to their randomisation date.
  • Post-operative scans should be performed within 28 days prior to randomisation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →